Peer-reviewed veterinary case report
Effects of synthetic BNP1-32 on heart and kidneys in dogs with mitral
By Yata, Mariko et al.·Published in Journal of veterinary internal medicine·2019·Sydney School of Veterinary Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
- Species:
- dog
Plain-English summary
A group of seven male dogs with heart failure caused by a heart valve problem were given a synthetic treatment called BNP1-32 to see if it would help their condition. The dogs were already on medication for their heart issues, and the study tested BNP1-32 alone, furosemide (a common diuretic), and both together. While the BNP1-32 was quickly absorbed and showed some changes in urine, it did not improve heart or kidney function as hoped. The researchers concluded that this treatment might not be effective for dogs with chronic heart failure.
People also search for: dog heart failure treatment · BNP1-32 for dogs · furosemide for congestive heart failure in dogs
Abstract
BACKGROUND: The effects of synthetic brain natriuretic peptide (BNP1-32) on cardiorenal and renin angiotensin aldosterone system in dogs with naturally occurring congestive heart failure (CHF) are unknown. OBJECTIVES: To evaluate the cardiorenal and endocrine effects of SC administered synthetic canine BNP1-32, with or without furosemide, in dogs with CHF caused by myxomatous mitral valve disease (MMVD). ANIMALS: Seven client-owned male dogs with compensated American College of Veterinary Internal Medicine stage C CHF caused by MMVD on chronic treatment with furosemide, benazepril, and pimobendan. METHODS: A single-dose, crossover, pilot study. Each dog received a dose of BNP1-32 (5 μg/kg), furosemide (2 mg/kg), and both BNP1-32/furosemide (5 μg/kg and 2 mg/kg, respectively) SC with a 2-week washout period among each treatment. Between- and within-treatment effects were evaluated using linear mixed modeling with restricted maximum likelihood estimation and evaluation of least square differences. RESULTS: Rapid absorption of BNP1-32 and a corresponding rise in urinary cyclic guanosine monophosphate excretion was observed at 1-2 hours after any treatment containing BNP1-32 (P < .05). However, BNP1-32 did not influence measured cardiorenal variables. Plasma aldosterone concentrations were below quantifiable levels in majority of the samples. CONCLUSIONS AND CLINICAL IMPORTANCE: No beneficial cardiorenal effects were detected. It is possible that dogs with chronic CHF have a reduction in natriuretic peptide responsiveness.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30703246/